Dr. Saville has over thirty years of extensive experience in clinical research, ranging from inpatient care, academic institutions, large pharma, and small biotech. Prior to working with OBI, Dr. Saville held several key leadership roles, including as CMO at Shasqi Inc. from 2020 to 2021, and as VP, Oncology Clinical Development at Xencor Inc. from 2015 to 2020, focusing on bispecific antibody development in oncologic indications. During his tenure at Biogen from 2002 to 2011, Dr. Saville led clinical programs including rituximab (Rituxan), ibritumomab tiuxetan (Zevalin), and natalizumab (Tysabri), as well as several small molecule TKIs.
Dr. Saville received his M.D. from Northwestern University, completed his internal medicine residency at the University of Minnesota, and was a postdoctoral fellow and clinical attending physician at the National Cancer Institute, NIH. He is board-certified in internal medicine and medical oncology.